Following completion of the dose escalation phase in relapsed/refractory acute leukemia patients with FLT3 mutations, Biomea ...

Sight Sciences’ management is scheduled to present on Tuesday, May 27, 2025, at 09:00 am PT / 12:00 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the ...

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor conferences: ...

Alumis received an upfront license fee of $20.0 million in March 2025 and will receive an additional $20.0 million in near-term co-development payments, with potential for additional milestone ...

In March 2025, the European Patent Office issued a Notice of Allowance for a new patent application (European Patent Appl. No. 20798130.9) covering key aspects of BioRestorative’s allogeneic, ...

SeaStar Medical Holding Corporation (Nasdaq: ICU) a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life ...

First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC. Topline data from DENALI Part 2 anticipated by year end 2026 with the potenti ...

Codexis reiterated its full-year 2025 financial guidance originally issued on February 27, 2025, as follows: Total revenues are expected to be in the range of $64 million to $68 million.

Research and Development (R&D) expenses: R&D expenses totaled $20.0 million for the first quarter of 2025. These expenses include $1.7 million of non-cash stock-based compensation. During the first ...

Goldberg will sit down with CNBC’s Tim Seymour on Wednesday, June 4, for an exclusive conversation in the Special Events Area on the CMB exhibit floor. The discussion will dive into the fast-rising ...

Note: alfa pump® and DSR® are registered trademarks.

Ramsay Santé Group reported a consolidated revenue of €3,889m for the nine months period ending 31 March 2025, up 5.1% on a reported basis. Adjusted for changes in the consolidation scope and at ...